INTRODUCTION
Gastro-oesophageal reflux disease (GERD) is a common gastrointestinal disorder that causes substantial morbidity and has a negative impact on the quality of life. 1 Some 20-40% of the adult population in Western countries report symptoms of GERD. 2, 3 Oesophageal pain can closely mimic the characteristic features of cardiac pain, implying that GERD symptoms may be misclassified as coronary heart disease and vice versa. As both GERD and coronary heart disease are prevalent diseases in the population, they frequently co-exist and may further interact in producing chest pain. Furthermore, it has been argued that oesophageal disease may aggravate myocardial ischaemia. 4 Some studies have suggested that oesophageal acid stimulation can produce angina and significantly reduce coronary blood flow. 5, 6 Other studies have suggested that GERD is common in patients with coronary heart disease and may be increased by drug therapy for this condition. 7 The purpose of this study was to estimate the incidence of a new episode of myocardial infarction in newly diagnosed GERD patients and to compare it with that in an age-and sex-matched general population free of GERD. We also estimated the association between the risk of myocardial infarction and the use of acidsuppressing drugs in the cohort of newly diagnosed GERD patients.
POPULATION AND METHODS

Study design
A retrospective cohort study with nested case-control analysis was performed using data from the General Practice Research Database in the UK. Approximately three million residents in the UK are registered with general practitioners geographically distributed throughout the country who participate in the General Practice Research Database. This scheme consists of close to 2000 general practitioners who use computers in their offices for the purpose of recording medical patient information in a standard manner. They have agreed to provide the information anonymously to the Medicines Control Agency which organizes the information for use in research projects. The information recorded includes demographics, medical diagnoses, referrals to consultant and hospital, and a register of written prescriptions. Prescriptions are automatically produced from the computer and recorded on the patient's computerized file. The accuracy and completeness of the data have been documented in previous validation studies of the General Practice Research Database. [8] [9] [10] An additional requirement of this data resource is that the indication for any new course of therapy be entered into the computer.
Study cohorts
The source population included all individuals aged 18-79 years registered in the database and with at least 2 years of enrolment with the general practitioner before 1996. All patients with a first recorded diagnosis of GERD (start date) during the year 1996 were identified. In addition, patients with a diagnosis of GERD or cancer before 1996, as well as pregnant women in 1996, were removed. The computerized profiles of all patients detected by the computer search with a first ever code of GERD (gastro-oesophageal reflux, acid reflux, acid regurgitation, oesophagitis and heartburn) were reviewed manually to further exclude patients with past history, as well as patients with longterm use of acid-suppressing drugs without a specific treatment indication, such as peptic ulcer, gastritis or duodenitis. For a sample of GERD patients (n ¼ 232), a questionnaire was sent to the corresponding general practitioner to request confirmation of the GERD diagnosis based on the clinical history and tests performed. In 98% of the patients, the diagnosis of GERD was confirmed by the general practitioner and in 72% it was defined as the first episode of GERD. Finally, 7084 patients constituted the GERD cohort.
A comparison cohort free of GERD was randomly sampled (n ¼ 10 000) from the source population and a random date in 1996 was assigned (start date). The same exclusion criteria as applied to the GERD cohort were used. The comparison cohort was matched by age and sex to the GERD cohort. The two cohorts were followed from the start date until the earliest occurrence of one of the following endpoints: incident myocardial infarction, cancer, 80 years of age, death or September 2000. For all patients identified with a code of myocardial infarction during follow-up, the computerized profiles were reviewed manually. We excluded patients in whom a diagnosis of myocardial infarction was subsequently ruled out. Definite cases (confirmed by a consultant visit or hospitalization) were separated from potential cases. For all potential cases of myocardial infarction, a questionnaire was sent to the general practitioner requesting the confirmation of myocardial infarction and asking for all paper-based information related to the episode of myocardial infarction. A 93% response rate was obtained and 51% of all potential cases were confirmed as a new acute myocardial infarction episode on that date. The non-confirmed patients either had a final diagnosis of angina or long-standing coronary heart disease without a new episode of myocardial infarction. Incidence rates of myocardial infarction were computed for the GERD cohort and the general population cohort free of GERD. The proportion of patients developing myocardial infarction was also estimated in relation to the time of follow-up, and the relative risk of myocardial infarction associated with GERD was calculated using Cox proportional hazard regression. A case-control analysis was performed in which all myocardial infarction cases validated in both cohorts were used as cases (n ¼ 168) and the date of diagnosis of myocardial infarction was used as the index date. A group of 1948 patients with a random date generated during the study period was randomly sampled from the pool of the two study cohorts and used as controls. Odds ratios (OR) and 95% confidence intervals (CI) were computed for myocardial infarction associated with GERD and other risk factors.
Recorded information on smoking, body mass index, alcohol consumption and a history of heart failure, ischaemic heart disease, hypertension and diabetes was collected. Information on the drug treatment for GERD (H 2 -receptor antagonists, proton pump inhibitors and antacids) was extracted from the computerized records. Current use was assigned when the drug supply lasted until the index date or ended in the previous month. Short-term use was defined as a treatment duration of less than 3 months and long-term use as a treatment duration of more than 3 months. Past use was assigned when the end of the most recent prescription was more than 1 month before the index date, and non-use when there was no drug use recorded in the computerized files.
RESULTS
During a mean follow-up of 27 months (range, 1-49 months; s.d., 14 months), 76 patients developed a first myocardial infarction in the GERD cohort and 92 in the general population cohort free of GERD. The incidence rate of myocardial infarction in the general population was 4.0 per 1000 person-years (95% CI, 3.2-4.9) and 5.1 per 1000 person-years (95% CI, 4.1-6.4) in GERD patients. The relative risk of myocardial infarction in patients with GERD was 1.4 (95% CI, 1.0-1.9) compared with the general population after adjusting for age and sex. The increased risk was more apparent in patients between 40 and 60 years of age ( Figure 1 ). All the excess risk was concentrated in the very early phase of follow-up after the diagnosis of GERD, as shown in Figure 2 . During the first month of follow-up, GERD patients had an elevated relative risk of 11.1 (95% CI, 3.3-37.0). Excluding the first month, the age-and sex-adjusted relative risk of myocardial infarction was 1.1 (95% CI, 0.8-1.5) in GERD patients. Table 1 shows the effect of several risk factors on the occurrence of myocardial infarction. After adjusting for additional risk factors, the estimate of risk associated with GERD was 1.1 (95% CI, 0.8-1.6). The risk of myocardial infarction increased in those with previous ischaemic heart disease morbidity (OR, 5.4; 95% CI, 3.6-8.0) and diabetes (OR, 2.0; 95% CI, 1.2-3.5). Smoking was associated with a close to two-fold increased risk, and recent chest pain (within 6 months) was an important predictor of myocardial infarction (OR, 4.7; 95% CI, 2.6-8.7). When the two cohorts were studied separately, the risk associated with recent chest pain was noticeably increased in patients free of GERD (OR, 10.3; 95% CI, 4.4-24.4) and, to a much lesser extent, in the GERD cohort (OR, 1.8; 95% CI, 0.7-4.5). Chest pain recorded more than 6 months prior to myocardial infarction was not associated with an excess risk in either of the two cohorts. No association was found between the use of acid-suppressing drugs and the risk of myocardial infarction in GERD patients (Table 2) .
DISCUSSION
Our results suggest that GERD is not an independent predictor of myocardial infarction. An increased risk was observed in the immediate days after the initial diagnosis of GERD, but no excess risk was observed once this period of time was discounted. As oesophageal and cardiac causes of chest pain may sometimes be clinically indistinguishable, it is reasonable to suggest that prodromal ischaemic symptoms, in some instances, were misdiagnosed as reflux symptoms in the immediate phase after the onset of symptoms.
We are not aware of any other studies that have evaluated the impact of GERD on the risk of the development of myocardial infarction. However, the concomitant prevalence of coronary heart disease and oesophageal dysfunction has been reported in 10-70% of subjects in small case series. [11] [12] [13] Using simultaneous oesophageal pH monitoring and Holter monitoring in patients with coronary heart disease who had persistent chest pain despite optimal anti-angina therapy, Singh et al. found that 67% had at least one episode of chest pain that was related to an acid reflux event. 13 They also reported that nearly 75% of patients showed improvement in chest pain following treatment with acid-suppressing drugs. The definition of myocardial infarction was not based on specific biochemical markers, but on general practitioner assessment based on their records and patient's discharge letters. This approach may result in a slightly lower number of patients with a diagnosis of myocardial infarction compared with estimates from clinical studies. 14 Nevertheless, the incidence of coronary heart disease observed in the general population cohort in this study is in line with recent results from populations in the UK.
15
A positive association was found with myocardial infarction for all known risk factors, such as smoking and previous heart disease. For some, such as hyperlipidaemia and heart failure, the risk estimates were not more statistically significant once all risk factors studied were adjusted for simultaneously. A doubling in risk of myocardial infarction associated with smoking and diabetes has been reported in men and women in several populations. 16 In our study, the 6-month period after the diagnosis of chest pain was associated with a close to 10-fold increased risk of myocardial infarction in patients free of GERD, but to a much lesser extent in the GERD cohort. In the West of Scotland Coronary Prevention Study, self-reporting of angina by the Rose Questionnaire was associated with a 54% increase in the risk of coronary heart disease-associated death or non-fatal myocardial infarction, and the consumption of nitrates presented a 90% increase in risk. 17 Chest pain, as reported in this study, covered not only stable angina pectoris, but also chest pain developing in the immediate pre-infarction period. Our data indicate that chest pain is a good predictor of subsequent myocardial infarction, especially in the general population free of GERD. In summary, our results suggest that GERD is not an independent predictor of myocardial infarction and the use of acid-suppressing drugs is not associated with a risk of myocardial infarction in the GERD cohort. The increase in risk observed in the immediate days after the first recorded diagnosis of GERD is most likely a reflection of prodromal ischaemic symptoms being initially misinterpreted as reflux symptoms. * Odds ratio (OR) adjusted for age, sex, calendar year, smoking and co-morbidity (diabetes, hypertension, heart failure, ischaemic heart disease), estimated by multiple regression analysis.
